

Medicines Patent Pool Statement for WIPO GA 2026 – July 7th-15th

The Medicines Patent Pool (MPP) is committed to active engagement with WIPO and its Member States. In recent years, MPP has presented its free database **MedsPaL** in SCP discussions on Patents and Health. **MedsPaL** supports access to essential health products providing patent and licence information, particularly in low- and middle-income countries. It now covers all medicines added to the 2025 WHO Essential Medicines List and candidate treatments for Ebola.

In May, MPP also announced a voluntary licence agreement with Roche for baloxavir marboxil, a WHO-recommended influenza antiviral, enabling generic supply in 129 low- and middle-income countries. This could be an important tool for response to possible future influenza pandemic.

Finally, I take the opportunity to inform WIPO Member States that the **WHO-MPP mRNA Technology Transfer Programme, which** has been supporting the development of manufacturing capacity in 15 countries across multiple regions, will soon be entering its second phase. Initially focused on COVID-19, it now supports development of mRNA vaccines and therapeutics for other diseases.

MPP looks forward to continued engagement and sharing further updates.